FDA advisers vote against sleep peptide as they debate safety and health claims

The FDA’s advisory committee is meeting for two days to discuss whether seven peptides — which have become popular in wellness circles — should be allowed to be compounded.

By Jaimy Lee

Inside the unconventional FDA panel that could reshape the peptide industry

Peptides are under scrutiny in an FDA meeting running July 23-24 Olena Malik/Getty Images An unconventional FDA panel is reviewing peptide safety, focusing on banned therapeutic peptides. The FDA raised concerns over peptide safety, citing immune reactions and a lack of evidence of efficacy. Better access to peptides could open up a multibillion-dollar market for telehealth companies. Nearly 2 years after Robert F. Kennedy Jr. vowed to end the FDA's "war" on peptides, he has convened an un...